L. Myasoutova

Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1

Joachim Sieper, Jan Lenaerts, J. Wollenhaupt et al. · Annals of the Rheumatic Diseases · 2013 · 213 citations · Full text

Medicine, Pharmacotherapy, Pain Management +16

A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis

Dae‐Hyun Yoo, Chang‐Hee Suh, Seung Cheol Shim et al. · Annals of the Rheumatic Diseases · 2016 · 81 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2

Joachim Sieper, Jan Lenaerts, J. Wollenhaupt et al. · Annals of the Rheumatic Diseases · 2013 · 64 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +10

Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis

Won Park, Chang‐Hee Suh, Seung Cheol Shim et al. · BioDrugs · 2017 · 43 citations · Full text

Medicine, Pharmacotherapy, Immunotherapy +11

Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial

Dae‐Hyun Yoo, Chang‐Hee Suh, Seung Cheol Shim et al. · BioDrugs · 2017 · 32 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacotherapy +16